Yes, atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021. It is a prescription medication used for the preventive treatment of episodic migraine in adults.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a small protein involved in migraine and pain pathways in the body. By blocking CGRP, atogepant helps reduce the frequency of migraine attacks. Clinical trials have shown that atogepant can reduce the number of monthly migraines, the number of monthly headache days, and the need for other migraine medications.
Atogepant is available in tablet form and comes in three strengths: 10 mg, 30 mg, and 60 mg. The usual adult dose for preventing migraines is one tablet taken orally once daily, with or without food. It's important to take atogepant at the same time each day, regardless of whether you have a migraine.
Before starting atogepant, inform your healthcare provider if you have:
Common side effects of atogepant include:
Atogepant can interact with other medications. Inform your doctor if you are taking any of the following:
Atogepant, under the brand name Qulipta, is an FDA-approved medication for the preventive treatment of episodic migraine in adults. It is a once-daily oral tablet that has been shown to effectively reduce the frequency of migraines. Always take atogepant as directed by your healthcare provider and inform them of any other medications you are taking to avoid potential interactions.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!